SORT-OUT IV trial compares XIENCE V, CYPHER Stent in major acute coronary events

Investigators reported results of SORT-OUT IV, comparing Cordis Corporation's CYPHER® Sirolimus-eluting Coronary Stent and Abbott's XIENCE V ® Everolimus-eluting Stent in the primary endpoint of MACE (major acute coronary events) at nine months. These findings were presented at the TCT annual meeting, (TCT 2010)held last week in Washington DC. This study adds to the unmatched body of safety and efficacy data on the CYPHER® Stent with this comparison to the more recently approved XIENCE V® Stent in a contemporary setting.

“The unique design characteristics of the CYPHER® Stent continue to make it an essential treatment option for today's interventional cardiologists.”

"The SORT OUT consortium has used CYPHER® Stent as the comparator in a number of studies and to date, no newer stent has proven a benefit over CYPHER® Stent in terms of safety or efficacy," said Campbell Rogers, M.D., Chief Scientific Officer and Head, Global Research and Development, Cordis Corporation. "The safety and efficacy of the CYPHER® Stent in this real-world randomized study reinforce the excellent sustained clinical outcomes consistently seen over the last 10 years."

The large randomized trial SORT OUT IV included more than 2,600 patients across a wide range of lesion and patient complexity. The study was designed to test whether the XIENCE V® stent is non-inferior to the CYPHER® stent. Both drug-eluting stents performed better than planned for the composite endpoint of MACE (4.9 % for XIENCE V® Stent vs. 5.2% for CYPHER® Stent); these data support the non-inferiority of the XIENCE stent over the CYPHER stent (non-inferiority>

"The SORT OUT IV trial demonstrates that both drug eluting stents perform extremely well," said Rogers. "The unique design characteristics of the CYPHER® Stent continue to make it an essential treatment option for today's interventional cardiologists."